Verition Fund Management
FATE icon

Verition Fund Management’s Fate Therapeutics FATE Stock Holding History

Verition Fund Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-53,585
Closed -$88.4K – 3443
2024
Q4 		$88.4K Buy
+53,585
New +$135K ﹤0.01% 3089
2024
Q3 		– Sell
-36,675
Closed -$120K – 3286
2024
Q2 		$120K Buy
+36,675
New +$161K ﹤0.01% 2706
2023
Q4 		– Sell
-52,654
Closed -$112K – 2437
2023
Q3 		$112K Buy
+52,654
New +$174K ﹤0.01% 2106
2023
Q1 		– Sell
-12,744
Closed -$129K – 2264
2022
Q4 		$129K Buy
+12,744
New +$239K ﹤0.01% 1820
2021
Q4 		– Sell
-12,755
Closed -$756K – 2628
2021
Q3 		$756K Sell
12,755
-9,156
-42% -$718K 0.01% 1048
2021
Q2 		$1.9M Buy
+21,911
New +$1.77M 0.02% 551

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Verition Fund Management's FATE Position: Q1 2025 in Review

Verition Fund Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 53,585 shares — an estimated $88.4K sold.

Verition Fund Management first reported a position in FATE in Q2 2021 and held it in 6 quarters. The position peaked at $1.9M in Q2 2021. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Verition Fund Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Verition Fund Management sold 53,585 Fate Therapeutics shares in Q1 2025, an estimated $88.4K.
  • Verition Fund Management first reported a position in Fate Therapeutics in Q2 2021 and held it in 6 quarters.
  • Verition Fund Management's Fate Therapeutics position peaked at $1.9M in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Verition Fund Management's 13F filing for Q1 2025, filed 15 May 2025.